vs

Side-by-side financial comparison of IDT CORP (IDT) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $322.8M, roughly 1.9× IDT CORP). Royalty Pharma plc runs the higher net margin — 34.4% vs 6.9%, a 27.5% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 4.3%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 4.4%).

IDT Corporation is a multinational provider of cloud communications, point of sale systems, unified communications, and financial services foreign exchange services for selected clients. It has units dedicated for businesses and consumers such as the Boss Revolution pre-paid phone cards, headquartered in Newark, New Jersey.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

IDT vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.9× larger
RPRX
$622.0M
$322.8M
IDT
Growing faster (revenue YoY)
RPRX
RPRX
+0.5% gap
RPRX
4.8%
4.3%
IDT
Higher net margin
RPRX
RPRX
27.5% more per $
RPRX
34.4%
6.9%
IDT
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
4.4%
IDT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
IDT
IDT
RPRX
RPRX
Revenue
$322.8M
$622.0M
Net Profit
$22.4M
$214.2M
Gross Margin
36.6%
Operating Margin
9.6%
62.4%
Net Margin
6.9%
34.4%
Revenue YoY
4.3%
4.8%
Net Profit YoY
29.6%
2.9%
EPS (diluted)
$0.89
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IDT
IDT
RPRX
RPRX
Q4 25
$322.8M
$622.0M
Q3 25
$316.6M
$609.3M
Q2 25
$302.0M
$578.7M
Q1 25
$303.3M
$568.2M
Q4 24
$309.6M
$593.6M
Q3 24
$308.8M
$564.7M
Q2 24
$299.6M
$537.3M
Q1 24
$296.1M
$568.0M
Net Profit
IDT
IDT
RPRX
RPRX
Q4 25
$22.4M
$214.2M
Q3 25
$16.9M
$288.2M
Q2 25
$21.7M
$30.2M
Q1 25
$20.3M
$238.3M
Q4 24
$17.2M
$208.2M
Q3 24
$36.8M
$544.0M
Q2 24
$5.6M
$102.0M
Q1 24
$14.4M
$4.8M
Gross Margin
IDT
IDT
RPRX
RPRX
Q4 25
36.6%
Q3 25
36.2%
Q2 25
37.1%
Q1 25
37.0%
Q4 24
34.8%
Q3 24
33.1%
Q2 24
32.4%
Q1 24
32.7%
Operating Margin
IDT
IDT
RPRX
RPRX
Q4 25
9.6%
62.4%
Q3 25
6.9%
70.1%
Q2 25
8.8%
36.3%
Q1 25
9.3%
94.0%
Q4 24
7.6%
60.9%
Q3 24
6.5%
Q2 24
3.8%
50.2%
Q1 24
5.4%
-13.0%
Net Margin
IDT
IDT
RPRX
RPRX
Q4 25
6.9%
34.4%
Q3 25
5.3%
47.3%
Q2 25
7.2%
5.2%
Q1 25
6.7%
41.9%
Q4 24
5.6%
35.1%
Q3 24
11.9%
96.3%
Q2 24
1.9%
19.0%
Q1 24
4.9%
0.8%
EPS (diluted)
IDT
IDT
RPRX
RPRX
Q4 25
$0.89
$0.49
Q3 25
$0.67
$0.67
Q2 25
$0.86
$0.07
Q1 25
$0.80
$0.55
Q4 24
$0.68
$0.46
Q3 24
$1.45
$1.21
Q2 24
$0.22
$0.23
Q1 24
$0.57
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IDT
IDT
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$189.3M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$320.7M
$9.7B
Total Assets
$654.9M
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IDT
IDT
RPRX
RPRX
Q4 25
$189.3M
$618.7M
Q3 25
$226.5M
$938.9M
Q2 25
$199.9M
$631.9M
Q1 25
$142.2M
$1.1B
Q4 24
$148.0M
$929.0M
Q3 24
$164.6M
$950.1M
Q2 24
$139.8M
$1.8B
Q1 24
$141.1M
$843.0M
Total Debt
IDT
IDT
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
IDT
IDT
RPRX
RPRX
Q4 25
$320.7M
$9.7B
Q3 25
$305.1M
$9.6B
Q2 25
$286.2M
$9.5B
Q1 25
$271.6M
$9.8B
Q4 24
$260.6M
$10.3B
Q3 24
$246.2M
$10.3B
Q2 24
$214.5M
$9.8B
Q1 24
$211.8M
$9.9B
Total Assets
IDT
IDT
RPRX
RPRX
Q4 25
$654.9M
$19.6B
Q3 25
$626.2M
$19.3B
Q2 25
$600.9M
$18.3B
Q1 25
$575.7M
$17.6B
Q4 24
$554.6M
$18.2B
Q3 24
$550.1M
$18.0B
Q2 24
$517.3M
$17.7B
Q1 24
$521.8M
$16.1B
Debt / Equity
IDT
IDT
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IDT
IDT
RPRX
RPRX
Operating Cash FlowLast quarter
$-10.1M
$827.1M
Free Cash FlowOCF − Capex
$-16.0M
FCF MarginFCF / Revenue
-4.9%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
-0.45×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$95.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IDT
IDT
RPRX
RPRX
Q4 25
$-10.1M
$827.1M
Q3 25
$31.0M
$702.6M
Q2 25
$75.7M
$364.0M
Q1 25
$20.2M
$596.1M
Q4 24
$164.0K
$742.5M
Q3 24
$25.4M
$703.6M
Q2 24
$9.5M
$658.2M
Q1 24
$28.4M
$664.6M
Free Cash Flow
IDT
IDT
RPRX
RPRX
Q4 25
$-16.0M
Q3 25
$25.7M
Q2 25
$70.3M
Q1 25
$15.3M
Q4 24
$-5.1M
Q3 24
$20.1M
Q2 24
$4.7M
Q1 24
$23.9M
FCF Margin
IDT
IDT
RPRX
RPRX
Q4 25
-4.9%
Q3 25
8.1%
Q2 25
23.3%
Q1 25
5.1%
Q4 24
-1.7%
Q3 24
6.5%
Q2 24
1.6%
Q1 24
8.1%
Capex Intensity
IDT
IDT
RPRX
RPRX
Q4 25
1.8%
Q3 25
1.7%
Q2 25
1.8%
Q1 25
1.6%
Q4 24
1.7%
Q3 24
1.7%
Q2 24
1.6%
Q1 24
1.5%
Cash Conversion
IDT
IDT
RPRX
RPRX
Q4 25
-0.45×
3.86×
Q3 25
1.84×
2.44×
Q2 25
3.49×
12.06×
Q1 25
0.99×
2.50×
Q4 24
0.01×
3.57×
Q3 24
0.69×
1.29×
Q2 24
1.71×
6.45×
Q1 24
1.97×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IDT
IDT

IDT Digital Payments$104.4M32%
IDT Global$60.2M19%
BOSS Revolution$45.7M14%
National Retail Solutions$39.3M12%
BOSS Revolution Money Transfer$36.3M11%
Net2phone$23.9M7%
Other$8.0M2%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons